Needham & Company Reinstates Coverage on Hologic (HOLX) at Buy; The 3-D Upgrade Cycle is Just Around the Corner
Tweet
Share
E-mailGet Alerts HOLX Hot Sheet
Price: $76.01 --0%
Rating Summary:
6 Buy, 28 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
6 Buy, 28 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Needham & Company reinstates coverage on Hologic (NASDAQ: HOLX) with a Buy. PT $22.00.
Needham analyst says, "We think a 3-D mammography upgrade cycle is
imminent and likely to drive the shares higher just as a transition from film to digital did a few years ago. Outside of the mammography field, the company is well positioned to benefit from the general economic recovery."
"For FY12 we are forecasting revenue growth of 7%, to $1.923 B. These estimates are consistent with management’s guidance for revenue of $1.9-1.925. For FY13 we are forecasting revenue growth of 7%, to $2.1 B, compared to the consensus of $2.0 B...Our FY12 pro forma estimate, which excludes non-cash expenses like depreciation, amortization and certain interest expenses, is $1.35 compared to the consensus of $1.36. For FY13 our pro forma EPS estimate is $1.48 compared to the consensus of $1.45."
For an analyst ratings summary and ratings history on Hologic click here. For more ratings news on Hologic click here.
Shares of Hologic closed at $17.16 yesterday.
Needham analyst says, "We think a 3-D mammography upgrade cycle is
imminent and likely to drive the shares higher just as a transition from film to digital did a few years ago. Outside of the mammography field, the company is well positioned to benefit from the general economic recovery."
"For FY12 we are forecasting revenue growth of 7%, to $1.923 B. These estimates are consistent with management’s guidance for revenue of $1.9-1.925. For FY13 we are forecasting revenue growth of 7%, to $2.1 B, compared to the consensus of $2.0 B...Our FY12 pro forma estimate, which excludes non-cash expenses like depreciation, amortization and certain interest expenses, is $1.35 compared to the consensus of $1.36. For FY13 our pro forma EPS estimate is $1.48 compared to the consensus of $1.45."
For an analyst ratings summary and ratings history on Hologic click here. For more ratings news on Hologic click here.
Shares of Hologic closed at $17.16 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Coherent (COHR) PT Raised to $420 at Needham
- York Space Systems (YSS) PT Lowered to $18 at Needham
- Celcuity Inc (CELC) PT Lowered to $140 at Needham
Create E-mail Alert Related Categories
New CoverageRelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
